Our board had paid just shy of "6 X PotentialEBITDA" for Teva according to media report below I found.
Now our current board are endorsing a sale at a little over "1 X actual EBITDA" when you take out the cash surplus handed over maybe not even.
I wish the board purchased the Teva portfolio at the equivalent, our SP would have been much healthier with far lower write offs
We have possibly sunk more costs on buying Nextstellis and marketing the product then what is being offered for the whole business plus other woman's health products. Products that we possibly paid 6 times earnings for?
This is why I will be voting a resounding No as the offer is well below industry norms.
I hope the independent expert is independent and concludes the same.
Below is the article extract.
MYX Price at posting:
$7.22 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)